Primary source Pharmaceutics (MDPI): From Platform Development to Scale-Up: Stable Producer Cell Line-Based Lentiviral Vector Manufacturing

VIVEbiotech, a company based in Donostia-San Sebastian, Spain, and co-authors have published a peer-reviewed paper on scaling a stable producer cell line (SCL) platform for lentiviral vector (LVV) manufacturing. The paper appeared in Pharmaceutics on 6 October 2026. This note covers the abstract only: the full text could not be opened from our systems, so nothing below goes beyond what the abstract states.
What the study set out to do
The abstract describes SCLs as a promising alternative for LVV manufacturing, offering improved reproducibility and reduced manufacturing costs. The authors’ group had earlier built an SCL generation platform on a well-characterized packaging cell line, with successful vector production at laboratory scale. The new study asks whether that platform scales, and which parameters drive production performance, such as cell density, harvest timing or pH.
What the abstract reports
- Mildly acidic culture conditions and extended harvest periods contribute to increased LVV titers (the amount of vector produced per volume of culture).
- The authors compared strategies for integrating the vector genes into the cell genome. Transposase-mediated integration is described as a precise and stable approach that minimizes concatemer formation (repeated copies joined end to end) and tandem rearrangements.
- The platform was extended through extensive genetic characterization and improved integration methods.
The authors conclude that their stable producer cell line is a scalable, genetically characterized and consistent LVV production platform, supporting its potential for large-scale manufacturing.
What the abstract does not say
The abstract gives no titer values, no bioreactor type or volume, and no pH setpoint or harvest duration. It does not say how much titer improved, so the size of the effect cannot be stated here. Those details would be in the full text.
Sources
- Pharmaceutics (MDPI), From Platform Development to Scale-Up: Stable Producer Cell Line-Based Lentiviral Vector Manufacturing, 6 Oct 2026 (abstract via Crossref).

